Kalvista Pharmaceuticals (KALV) Stock Rating Lowered by BidaskClub

Share on StockTwits

BidaskClub cut shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a buy rating to a hold rating in a report issued on Tuesday morning, BidAskClub reports.

Several other analysts have also recently commented on KALV. Zacks Investment Research cut shares of Kalvista Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Thursday, February 21st. ValuEngine upgraded shares of Kalvista Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, February 4th. Needham & Company LLC assumed coverage on shares of Kalvista Pharmaceuticals in a research note on Wednesday, March 20th. They issued a buy rating and a $35.00 price target on the stock. Finally, TheStreet upgraded shares of Kalvista Pharmaceuticals from a d+ rating to a c- rating in a research note on Thursday, December 20th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $28.60.

Shares of KALV stock opened at $25.27 on Tuesday. Kalvista Pharmaceuticals has a 52 week low of $7.73 and a 52 week high of $34.92.

Kalvista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.22. The business had revenue of $3.89 million for the quarter, compared to analysts’ expectations of $3.97 million. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. Sell-side analysts expect that Kalvista Pharmaceuticals will post -1.43 EPS for the current year.

In other news, major shareholder Svlsf Iv, Llc sold 22,800 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $29.49, for a total value of $672,372.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Venrock Healthcare Capital Par sold 500,000 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $28.75, for a total transaction of $14,375,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,097,573 shares of company stock worth $29,479,165. Insiders own 38.40% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc increased its holdings in shares of Kalvista Pharmaceuticals by 152.4% in the 3rd quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock worth $6,558,000 after buying an additional 179,092 shares during the last quarter. Vanguard Group Inc. grew its holdings in Kalvista Pharmaceuticals by 152.4% during the 3rd quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock valued at $6,558,000 after purchasing an additional 179,092 shares during the last quarter. Stonepine Capital Management LLC bought a new position in Kalvista Pharmaceuticals during the 3rd quarter valued at about $3,053,000. Fosun International Ltd bought a new position in Kalvista Pharmaceuticals during the 4th quarter valued at about $2,444,000. Finally, Renaissance Technologies LLC grew its holdings in Kalvista Pharmaceuticals by 228.5% during the 3rd quarter. Renaissance Technologies LLC now owns 117,349 shares of the specialty pharmaceutical company’s stock valued at $2,595,000 after purchasing an additional 81,621 shares during the last quarter. Hedge funds and other institutional investors own 77.37% of the company’s stock.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

See Also: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.